當(dāng)前位置：   首頁(yè) > 需求大廳

求購(gòu)乙酰半胱氨酸注射液信息，要求內(nèi)容正確。   [更多]

想要這個(gè)藥的說(shuō)明書(shū)，溶出曲線及檢測(cè)方式（中文的）   [更多]

求混合糖電解質(zhì)注射液的IMS全球銷售數(shù)據(jù)，日本的商品名：TRIFLUID Injection   [更多]

1、Arzneimittelforschung. 1985;35(7A):1203-8. Ohashi S, Iwatani M, Hyakuna Y, Morioka Y. Thermographic evaluation of the hemodynamic effect of the antithrombotic drug cilostazol in peripheral arterial occlusion. 2、Arzneimittelforschung. 1985;35(7A):1149-54. K Kawamura, K Watanabe, Y Kimura. Effect of cilostazol, a new antithrombotic drug, on cerebral circulation 3、Gel formation of cefpodoxime proxetil 4、Gas chromatographic analysis of fosfomycin in plasma for pharmacokinetic analysis. GK Webster, RG Bell - Journal of AOAC International, 1999 - europepmc.org 5、Rydell N, Butler J, Balazs EA. Hyaluronic acid in synovial fluid.Ⅵ. Effect of intra-articular injection of hyaluronic acid on the clinical symptoms of the arthritis in track horses. Acta Vet Scand, 1970,11:139~146 6、Peyron JG, Balazs EA. Preliminary clinical assessment of Na-hyaluronate injection into human arthritic joints. Pathol Biol, 1974, 22:731~736 7、Weiss C, Balazs EA, St Onge R, et al. Clinical studies of the intra-articular injection of Healon in the treatment of osteoarthritis of human knee. Semin Arhtritis Rheum, 1980, 11(Suppl 1):143~144 8、Punzi L, Schiavon F, Ramonda R, et al. Intra-articular hyaluronic acid in the treatment of inflammatory and non-inflammatory knee diffusions. Curr Ther Res, 1988, 43:643~647 9、Nolan JP, reducing Catheter Related Bacteraemia in Haemodialysis. Vascular Access Soc. 5th Int. Congress of Vascular Access Soc, Nice, 2007 10、Arzneimittelforschung. 1984;34(9):948-52. Iron derivatives of modified milk protein.   [更多]

具體要求： 根據(jù)已知企業(yè)名稱（寫(xiě)法不規(guī)范） 去CFDA http://app1.sfda.gov.cn/datasearchcnda/face3/base.jsp?tableId=25&tableName=TABLE25&title=%B9%FA%B2%FA%D2%A9%C6%B7&bcId=152904713761213296322795806604 或 藥智數(shù)據(jù)https://db.yaozh.com/pijian 查找對(duì)應(yīng)的規(guī)范企業(yè)名稱 無(wú)法確認(rèn)的需備注好原因 規(guī)范數(shù)據(jù)按照0.05元/條（10000條500元） 備注數(shù)據(jù)按照0.01元/條（10000條100元） 準(zhǔn)確率要求98%。   [更多]

文獻(xiàn)： 1、" Posaconazole as salvage therapy in a patient with disseminated zygomycosis: case report and review of the literature. " Pharmacotherapy 2007;27:290–8. Page RL, Schwiesow J, Hilts A. 2、Mucormycosis treated with posaconazole: review of 96 case reports. Crit Rev Microbiol 2013;39:310–24. Vehreschild JJ, Birtel A, Vehreschild MJGT, et al. 3、Tarantino MD, Fogarty P, Mayer B, Vasey SY, Brainsky A. Efficacy of eltrombopag in management of bleeding symptoms associated with chronic immune thrombocytopenia. Blood Coagul Fibrinolysis. 2013 Apr;24(3):284-96. doi: 10.1097/MBC.0b013e32835fac99. 4、J Med Chem, 51: 4632～4640. Org. Process Res. Dev. 2019, 23, 9, 2057-2068 Pharmazie 73(9):494-497 · September 2018 5、中國(guó)醫(yī)藥工業(yè)雜志 2012， 43（8）， 644-646 6、精細(xì)化工中間體2013，43（2），46-48 7、精細(xì)化工中間體2011，41（4），46-48 8、中國(guó)現(xiàn)代應(yīng)用藥學(xué)2011，28（1），58-59 9、Chemical biology&Drug Design 2014, 83(3), 306-316 10、Letters in organic chemistry 2012, 9(4), 276-279 11、Medicines Evidence Commentary : Chronic kidney disease: calcium-based versus non-calcium-based phosphate binders Source: National Institute for Health and Care Excellence - NICE - 21 January 2014 - Publisher: National Institute for Health and Care Excellence (NICE) 12、double-blind comparison of calcium chloride and calcium gluconate therapies for hypocalcemia in critically ill children 13、J. Med. Chem. 2018, 61, 5304?5322. 14、Chem. Biol. Drug Des. 2014, 83, 306?316. 15、J. Pharm. Biomed. Anal. 2009, 50, 144?150. 16、Int. J. Pharm. Sci. 2016, 8, 97?102. 17、J. Pharm. Biomed. Anal. 2010, 52, 493?507. 18、Org. Process Res. Dev. 2013, 17, 1036?1041. 19、Beilstein J. Org. Chem. 2011, 7, 442? 495. 20、Bioorg. Med. Chem. Lett. 2014, 24, 1108?1110. 21、New Activated PEG Derivatives for Affinity Partitioning 22、Population incidence and mortality of sepsis in an urban African setting 2013-2016 23、Association of the Quick Sequential (Sepsis-Related) Organ Failure Assessment (qSOFA) Score With Excess Hospital Mortality in   [更多]

有生產(chǎn)許可證等必要資質(zhì)   [更多]

求IMS數(shù)據(jù)庫(kù)復(fù)方醋酸鈉林格注射液銷售數(shù)據(jù)，目前國(guó)內(nèi)獲批的此品種有兩個(gè)名字，希望能查全 復(fù)方醋酸鈉林格是大輸液，國(guó)內(nèi)的名字叫復(fù)方醋酸鈉林格注射液，也叫鈉鉀鎂鈣葡萄糖注射液，日本大冢上市的名字叫：電解質(zhì)輸液（1％ブドウ糖加酢酸リンゲル液），商品名叫：Physio 140 Injection（フィジオ140 輸液）   [更多]

收集了全國(guó)各省市的藥品中標(biāo)信息，為了保證給大家有更準(zhǔn)確及時(shí)的信息，需要 對(duì)藥品中標(biāo)信息數(shù)據(jù)庫(kù)及時(shí)更新，現(xiàn)請(qǐng)人進(jìn)行最新中標(biāo)數(shù)據(jù)的收集整理。 工作內(nèi)容：及時(shí)查到最新公布的藥品中標(biāo)信息，并將最新的文件按指定要求 處理成規(guī)范的格式(excel表)。交稿如發(fā)現(xiàn)遺漏，反饋后望及時(shí)補(bǔ)充。 補(bǔ)充月份：2019年8月-2020年1月（共6個(gè)月）   [更多]

求購(gòu)“Citicoline”《 USP42-NF37 》的藥典標(biāo)準(zhǔn)一份.   [更多]